The Oxfendazole Development Group is a 501c3 nonprofit organization formed and operated exclusively for charitable purposes specifically for the purpose of engaging in research and development of pharmaceutical treatments to help eliminate neglected tropical diseases NTDs and to facilitate access to such treatments for individuals in need.
Reported officers (all unpaid)
No paid executives reported in 2024. OXFENDAZOLE DEVELOPMENT GROUP reported 5 unpaid officers and board members on its 990.
Funded by
Private foundations whose Form 990-PF Part XV grants matched this organization.
Revenue and expenses over time
OXFENDAZOLE DEVELOPMENT GROUP reported revenue and expenses across 2 filing years.
What Medical Research executives earn in Pennsylvania
OXFENDAZOLE DEVELOPMENT GROUP reported no executive compensation in its latest filing. For context, the highest-paid executive at a comparable medical research organization in Pennsylvania earns a median of $83,694.
These are medical research sector-wide figures, not this organization's reported pay. Based on 53 organizations across 53 filings (2023 – 2024).
See full Medical Research pay data for Pennsylvania →Common questions about OXFENDAZOLE DEVELOPMENT GROUP
What are OXFENDAZOLE DEVELOPMENT GROUP's revenue and expenses?
In 2024, OXFENDAZOLE DEVELOPMENT GROUP reported $23k in total revenue and $852k in total expenses on its IRS Form 990.
Compare any role, sector, or revenue band
Build your own benchmark from millions of reported positions.
Learn More About Nonprofit Compensation
Guides to help you understand and use this data
How to Look Up Nonprofit Salaries
Two approaches to finding executive compensation at any tax-exempt organization, from raw IRS filings to searchable databases.
Read moreAre Nonprofit Salaries Public?
What IRS Form 990 discloses about executive compensation, who has to report it, and how to look it up.
Read moreHow to Benchmark Nonprofit Executive Compensation
A step-by-step approach to using IRS Form 990 data for compensation benchmarking and peer comparison.
Read more